Ki-67 expression in breast carcinoma: Its association with grading systems, clinical parameters, and other prognostic factors - A surrogate marker?

Cancer

Volumn 97, Issue 5, 2003, Pages 1321-1331

  Trihia, Helen ^a   Murray, Susan ^b,c   Price, Karen ^b,d   Gelber, Richard D ^b,d,e   Golouh, Rastko ^f   Goldhirsch, Aron ^g,h   Coates, Alan S ^i,j   Collins, John ^k   Castiglione Gertsch, Monica ^l   Gusterson, Barry A ^a,m  

^a WESTERN INFIRMARY   (United Kingdom)

^b Intl B C Stud Grp Stat Ctr   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f INSTITUTE OF ONCOLOGY   (Slovenia)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h Oncol Inst of S Switzerland   (Switzerland)

ⁱ CANCER COUNCIL AUSTRALIA   (Australia)

^j UNIVERSITY OF SYDNEY   (Australia)

^k ROYAL MELBOURNE HOSPITAL   (Australia)

^l Intl B C Stud Grp Coord Ctr   (Switzerland)

^m UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

Bloom Richardson grade; Breast carcinoma; Histologic grade; Ki 67, MIB 1; Nottingham grade

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PROGESTERONE RECEPTOR;

ARTICLE; ASPIRATION BIOPSY; BLOOM RICHARDSON GRADE; BREAST CARCINOMA; CANCER GRADING; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MITOSIS RATE; NOTTINGHAM GRADE; ONCOGENE C ERB; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MULTIVARIATE ANALYSIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS;

EID: 20244374922     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11188     Document Type: Article

References (69)

1. Bloom HJG, Richardson WW. Histologic grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11:359-377.
2. Patey DH, Scarff RW. The position of histology in the prognosis of carcinoma of the breast. Lancet. 1928;1:801-804.
3. Bloom HJG. Prognosis in carcinoma of the breast. Br J Cancer. 1950;4:259-288.
4. Bloom HJG. Further studies on prognosis of breast carcinoma. Br J Cancer. 1950;4:347-367.
5. Black MM, Barclay THC, Hankey BF. Prognosis in breast cancer utilizing histologic characteristics of the primary tumor. Cancer. 1975;36:2048-2055.
6. Gusterson BA. Prognostic variables and future predictors of behavior and response. Recent results in cancer and research, vol 140. Berlin: Springer-Verlag, 1996.
7. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology. 1991;19:403-410.
8. Page DL, Ellis IO, Elston CW. Histologic grading of breast cancer. Let's do it. Am J Clin Pathol. 1995;103:123-124.
9. Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 1992;20:479-489.
10. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-2685.
11. Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995;13: 547-552.
12. Eisen T, Smith IE, Johnson S, et al. Randomized Phase II trial of infusional fluorouracil, epirubicin and cyclophosphamide versus infusional fluorouracil, epirubicin and cisplatin in patients with advanced breast cancer. J Clin Oncol. 1998;16: 1350-1357.
13. Powles TJ. Adjuvant therapy for early breast cancer: a time to refine. J Natl Cancer Inst. 1997;89:1652-1654.
14. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet. 1997;349:1864-1867.
15. Haffty BG, Ward B, Pathare P. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J Clin Oncol. 1997;15:691-700.
16. Davis BW, Gelber RD, Goldhirsch A, et al. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol. 1985;16:1212-1218.
17. Seidman JD, Schnaper LA, Aisner SC. Relationship of the size of the invasive component of the primary breast carcinoma to axillary lymph node metastasis. Cancer. 1995;75: 65-71.
18. Cady B, Stone M, Schuler JG, Thakur R, Wanner MA, Larin PT. The new era in breast cancer. Invasion, size and nodal involvement dramatically decreasing as a result of mammography screening. Arch Surg. 1996;131:301-308.
19. Makris A, Allred DC, Powles TJ, et al. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat. 1997;44:65-74.
20. Hall PA, Levison DA. Review: assessment of cell proliferation in histological material. J Clin Pathol. 1990;43:184-192.
21. Hall PA, Levison DA, Wright NA. Assessment of cell proliferation in clinical practice. Berlin: Springer Verlag, 1992.
22. Galand P, Degraef C. Cyclin/PCNA immunostaining as an alternative to tritiated thymidiline pulse labeling for marking S phase cells in paraffin sections from animal and human tissues. Cell Tissue Kinet. 1989;22:383-392.
23. Scott RJ, Hall PA, Haldane JS, et al. A comparison of immunohistochemical markers of cell proliferating with experimentally determined growth fraction. J Pathol. 1991;165: 173-178.
24. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31:13-20.
25. Gerdes J, Lemke H, Baisch H, Walker H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715.
26. Dalquen P, Baschiera B, Chaffard R, et al. MIB-1(Ki-67) immunostaining of breast cancer cells in cytologic smears. Acta Cytol. 1997;41:229-237.
27. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed, paraffin sections. J Pathol. 1992;168:357-363.
28. Walker RA, Camplejohn RS. Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. Br J Cancer. 1988;57:281-283.
29. Dawson AE, Norton JA, Weinberg DS. Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry. Am J Pathol. 1990; 136:1115-1124.
30. Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study: DNA flow cytometric analysis, and mitotic count. Cancer. 1990;65:1180-1184.
31. Sasaki K, Matsumura T, Tsujj T, Shinozaki F, Takahaski M. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer. 1988;62:989-993.
32. McCormick D, Yu C, Hobbs C, Hall PA. The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens. Histopathology. 1993;22:543-547.
33. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med. 1988;319:677-683.
34. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med. 1989;320:491-496.
35. Goldhirsch A, Gelber RD, Castiglione M, et al., for the International Breast Cancer Study Group. Present and future projects of the International Breast Cancer Study Group. Cancer. 1994;3(Suppl):1139-1149.
36. Gusterson BA, Gelber RD, Goldhirsch A, et al., for the International Breast Cancer Study Group. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992; 10:1049-1056.
37. Gusterson BA, Gelber RD, Goldhirsch A, et al., for the International Breast Cancer Study Group. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol/Classic Papers Current Comments. 2001;5:908-916.
38. Pestalozzi BC, Peterson HF, Gelber RD, et al. The prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol. 1997;15:1923-1931.
39. Pinder SE, Murray S, Ellis IO, et al. The importance of histological grade in invasive breast carcinoma and response to chemotherapy. Cancer. 1998;83:1529-1539.
40. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 1968;70:213-220.
41. Pearson, K. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling (series 5). Philosophical Magazine. 1900;50:157-175.
42. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B (Methodol). 1972;34:187-220.
43. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
44. Davis BW, Gelber RD, Goldhirsh A, et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer. 1986;58:2662-2670.
45. Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D, Rouesse J. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1010 patients, uniformly treated at the Institute Gustave-Roussy. J Clin Oncol. 1987;5:1378-1386.
46. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR): an improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989; 64:1914-1921.
47. von Hansemann D. Ueber assymetrische Zelltheilung in Epithelkrebsen und deren biologische Beteudung. Virchows Arch Pathol Anat. 1890;119:299-326.
48. von Hansemann D. Ueber die Anaplasie der Geschwulstzellen und die asymmetrische mitose. Virchows Arch Pathol Anat. 1892;129:436-449.
49. Salomon A. Beitrage zur Pathologie und Klinik der Mammacarcinome. Arch Klinischen Chirurgie. 1913;101:573-668.
50. Greenough RB. Varying degrees of malignancy in cancer of the breast. J Cancer Res. 1925;9:453-463.
51. Patey DH, Scarff RW. The position of histology in the prognosis of carcinoma of the breast. Lancet. 1928;1:801-804.
52. Elston CW. The assessment of histological differentiation in breast cancer. Aust NZ J Surg. 1984;54:11-15.
53. Frierson HF, Wolber RA, Berfan KW, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol. 1995;103:195-198.
54. Malaise EP, Chavaudra N, Tubiana M. The relationship between growth rate, labelling index and histological type of human solid tumors. Eur J Cancer. 1973;9:305-312.
55. Dean PN, Dolbeare F, Gratzner H, Rice GC, Gray JW. Cell-cycle analysis using a monoclonal antibody to BrdUrd. Cell Tissue Kinet. 1984;17:427-436.
56. Quirke P, Dyson JED. Flow cytometry: methodology and applications in pathology. J Pathol. 1986;149:79-87.
57. Franklin WA, Bibbo M, Doria MI, et al. Quantitation of estrogen receptor content and Ki-67 staining in breast carcinoma by the micro-TICAS image analysis system. Anal Quant Cytol Histol. 1987;9:279-283.
58. Stumpp J, Dietl J, Geppert M. Growth fraction in breast carcinoma determined by Ki-67 immunostaining: correlation with pathological and clinical variables. Gynaecol Obstet Invest. 1992;33:47-50.
59. Betta PG, Robutti F, Pilato FP, Spiroglio G, Bottero G. Correlation of proliferation activity with pathological features in breast carcinoma. Eur J Gynaecol Oncol. 1989; 10:433-437.
60. Bouzubar N, Walker KJ, Griffiths K, et al. Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer. 1989;59:943-947.
61. Wrba F, Chott A, Reiner A, Markis-Ritzinger EM, Holtzner JH. Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study. Oncology. 1989;46:255-259.
62. Sahin AA, Ro JY, Block MB, et al. Ki-67 immunostaining in node-negative Stage I/II breast carcinoma. Significant correlation with prognosis. Cancer. 1991;68:549-557.
63. Veronese SM, Gambacorta M. Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. Am J Clin Pathol. 1991;95:30-34.
64. Campani D, De-Negri F, Fabri R, et al. Estrogen, progesterone receptors and proliferating activity evaluated by immunocytochemistry in breast cancer. Int J Biol Markers. 1991; 6:144-150.
65. Di-Stefano D, Mingazzini PL, Scucchi L, Donnetti M, Marinozzi V. A comparative study of histopathology, hormone receptors, peanut lectin binding, Ki-67 immunostaining, and nucleolar organizer region-associated proteins in human breast cancer. Cancer. 1991;7:463-471.
66. Lee AK, Wiley B, Loda M, et al. DNA ploidy, proliferation and neu-oncogene protein overexpression in breast carcinoma. Mod Pathol. 1992;5:61-67.
67. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma O. p55 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlation with receptor status, proliferating markers, and clinical stage in human breast cancer. Am J Clin Pathol 1992;98:408-418.
68. Nicholson RI, McClelland RA, Finlay P, et al. Relationship between EGF-R, c-erbB-2 protein expression and Ki-67 immunostaining in breast cancer and hormone sensitivity. Br J Cancer. 1993;29A:1018-1023.
69. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lambertico P. Proliferation index as a prognostic marker in breast cancer. Cancer. 1993;71:3926-3931.